A
lexandria Real Estate Equities (NYSE: ARE) now carries a consensus “Reduce” rating from 14 research houses. Four analysts recommend selling, seven advise holding, and three suggest buying. The average 12‑month target price across recent reports is $79.38.
Recent commentary includes BMO Capital Markets launching coverage on Sept. 23 with an “outperform” rating and a $100 target; Evercore ISI cut its target from $104 to $74 on Oct. 31; BNP Paribas Exane lowered its target from $82 to $72 and downgraded to “underperform” on Oct. 28; BNP Paribas also shifted from “hold” to “strong sell” with an $82 target on Oct. 1; Jefferies set a $62 target and a “hold” rating on Nov. 3.
The stock opened at $52.30 on Friday, trading near its 1‑year low of $51.63 and 1‑year high of $112.42. Its 50‑day moving average sits at $73.95, while the 200‑day average is $74.80. Key ratios: debt‑to‑equity 0.65, current ratio 0.24, quick ratio 0.23. Market cap is $9.04 B, P/E –21.17, PEG 5.06, beta 1.29.
Earnings for the quarter ended Oct. 27 were $2.22 EPS, slightly below the consensus of $2.31, and revenue was $751.94 M versus the expected $752.90 M. Net margin was –13.43% and ROE –1.89%, with revenue down 5% YoY. FY 2025 guidance is $8.98‑$9.04 EPS; analysts project $9.32 EPS for the current year.
A quarterly dividend of $1.32 per share was paid on Oct. 15 to shareholders of record on Sept. 30, yielding 10.1% and annualizing to $5.28. The payout ratio stands at –213.77%.
Institutional activity is notable: Norges Bank added a $1.195 B stake in Q2; UBS Asset Management increased holdings by 1,022% in Q3, now owning 1.814 M shares worth $151.2 M; AQR Capital Management grew its position by 511.9% in Q1 to 1.518 M shares ($140.4 M); Invesco expanded by 39% in Q1 to 3.148 M shares ($291.2 M); Davenport & Co. surged 1,796% in Q2 to 835,789 shares ($60.8 M). Collectively, hedge funds and other institutions own 96.54% of ARE shares.
Founded in 1994, Alexandria is a leading life‑science REIT focused on collaborative campuses across major U.S. innovation hubs such as Boston, San Francisco, New York, San Diego, Seattle, Maryland, and the Research Triangle. While top analysts are currently favoring other stocks, Alexandria remains a prominent player in the life‑science real‑estate niche.
